The Top Three Holders Of Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) reached 91.25% versus a 1-year low price of $8.00. The stock was last seen -1.61% lower, reaching at $15.3 on 07/12/2018. At recent session, the prices were hovering between $14.95 and $15.75. This company shares are 79.74% off its target price of $27.5 and the current market capitalization stands at $1.49B. The recent change has given its price a -3.29% deficit over SMA 50 and -44.36% deficit over its 52-week high. The stock witnessed -3.47% declines, -21.94% declines and -12.07% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SGMO’s volatility during a week at 4.65% and during a month it has been found around 6.18%.

Sangamo Therapeutics, Inc. (SGMO) Top Holders

Institutional investors currently hold around $908 million or 58.5% in SGMO stock. Look at its top three institutional owners. Vanguard Group Inc owns $107.97 million in Sangamo Therapeutics, Inc., which represents roughly 7.25% of the company’s market cap and approximately 11.89% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 6,692,054 shares of the stock are valued at $104.06 million. The third largest holder is State Street Corp, which currently holds $70.55 million worth of this stock and that ownership represents nearly 4.73% of its market capitalization.

Sangamo Therapeutics, Inc. 13F Filings

At the end of March reporting period, 114 institutional holders increased their position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by some 10,598,287 shares, 90 decreased positions by 8,985,105 and 21 held positions by 38,823,682. That puts total institutional holdings at 58,407,074 shares, according to SEC filings. The stock grabbed 59 new institutional investments totaling 2,730,654 shares while 17 institutional investors sold out their entire positions totaling 678,043 shares.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Insider Trades

Multiple company employees have indulged in significant insider trading. Sangamo Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Sr. VP & Chief Medical Officer Conner Edward R. has sold 5,000 shares of Sangamo Therapeutics, Inc. (SGMO) in trading session dated Jul. 06, 2018. These shares are worth $79,000 and were traded at $15.8 each. The SEC filing shows that Yi Kathy performed a sale of 5,000 shares. The SVP & CFO disposed these shares by way of transaction on Jun. 15, 2018. The company’s shares were given away at $15.67 per share worth to an income of some $78,350 on account of Yi Kathy.

Sr. VP & Chief Medical Officer, Conner Edward R., sold 5,000 common shares of Sangamo Therapeutics, Inc. (SGMO) in the open market. In a transaction dated Jun. 06, 2018, the shares were put up for sale at an average price of $16.67, raking in a sum of $83,350. After this sale, 10,125 common shares of SGMO are directly owned by the insider, with total stake valued at $154,913.

In the transaction dated May. 15, 2018, the great number of shares disposed came courtesy the SVP & CFO; Yi Kathy disposed a total of 5,000 shares at an average price of $15.38, amounting to approximately $76,900. The insider now directly owns 7,250 shares worth $110,925.

Sangamo Therapeutics, Inc. (SGMO) Analyst Guide

Several analysts have released their opinion on Sangamo Therapeutics, Inc. (NASDAQ:SGMO), with 6 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.29 average brokerage recommendation.